Reviews
Provider reviews & value verdicts
Every GLP-1 telehealth provider we've run through the Cost-Efficiency Index, with its score and one-line value verdict. Tap any provider for its full cost breakdown, or compare them all on the value leaderboard.
- 94CoreAge Rx#1 · Grade A · PartnerBest value on the board: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser.
- 88Invigor Medical#2 · Grade B+ · PartnerSolid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog.
- 87ShedRx#3 · Grade B+ · PartnerThe lowest published tirzepatide cost among our partners, plus an oral/sublingual route — strong cost-per-month for the needle-averse.
- 86Eden#4 · Grade B · PartnerYou pay a premium per month, but you buy back certainty: all-50 access and high-disclosure clinical oversight that hold their value.
- 85AgelessRx#5 · Grade B · PartnerThe lowest published semaglutide cost on the board, with some brand-name access — but an undisclosed tirzepatide price leaves a hole in the value model.
- 88Found#6 · Grade B+ · EditorialThe cheapest identical price on both molecules nationwide — unbeatable raw cost-per-month, capped only by a coaching subscription you can't fully unbundle.
- 84Ro#7 · Grade B · EditorialThe widest formulary — brand-name and oral access — but opaque compounded pricing means you can't model the value until you're already in the funnel.
- 83Hims & Hers#8 · Grade B · EditorialNationwide reach and a slick app at a mid-market semaglutide price — but an undisclosed tirzepatide price leaves part of the value equation blank.
- 81Henry Meds#9 · Grade B− · EditorialA transparent flat-fee pioneer — the pricing is clean and modelable, but it now sits at the higher end, so the value per dollar has slipped.
Cost-Efficiency Index scores are editorial judgment per our methodology; facts reflect each provider's public disclosures at last review. Not medical advice.